Exciting advancements are on the horizon for Gene & Cell Therapies, particularly in the realm of treating hematologic and rare diseases. The anticipation surrounding the FDA approvals expected in 2024 is palpable, with each approval holding the potential to impact patient populations significantly. As INTERLINK® draws closer to the launch of Symphony Benefits Solution, we’re […]